Supernus Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the pr

Supernus Pharmaceuticals, Inc. Stock at a Glance

Supernus Pharmaceuticals, Inc. (SUPN) is currently trading at $44.41 with a market capitalization of $2.6B. The 52-week range spans from $30.83 to $59.68; the current price is 25.6% below the yearly high. Year-over-year revenue growth stands at +38.6%.

💰 Dividend

Supernus Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Supernus Pharmaceuticals, Inc. (SUPN) on consensus: Strong Buy. The average price target is $62.83, implying +41.48% from the current price. Analyst price targets range from $55.00 to $66.00.

Supernus Pharmaceuticals, Inc.: The Investment Case in Detail

Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 38.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 74.13%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 41.48% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 11.47% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The analyst consensus price target implies 41.48% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (11.47%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Supernus Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.